Related Experiment Video
Updated: Mar 22, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
Levosimendan. A promising future drug for refractory cardiac failure in children?
Supriya Kushwah1, Ashutosh Kumar2, K S Sahana3
1Assistant Professor, Department of Pediatrics, Yenepoya Medical College, Deralakatte, Mangalore, Karnataka, India.
Insights
Levosimendan effectively treated a young girl with severe heart failure from viral myocarditis. This inotropic agent improved cardiac function without increasing oxygen demand, offering a new treatment option.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Intravenous positive inotropic agents are crucial for acute decompensated heart failure (ADHF) with left ventricular systolic dysfunction.
- Levosimendan is a novel inotropic agent with unique mechanisms: ATP-dependent potassium channel opening and calcium sensitization.
Observation:
- A 12-year-old girl presented with viral myocarditis and dilated cardiomyopathy, experiencing biventricular failure and severe left ventricular dysfunction.
- Her condition was refractory to standard heart failure management protocols.
Findings:
- Treatment with levosimendan resulted in significant clinical improvement.
- Levosimendan enhanced cardiac contractility and performance while providing vasodilation, notably without increasing myocardial oxygen demand.
Implications:
- This case highlights levosimendan's potential efficacy in pediatric patients with severe heart failure unresponsive to conventional therapies.
- Levosimendan represents a promising therapeutic option for complex pediatric cardiomyopathies and myocarditis.
- Further research into levosimendan's role in pediatric cardiovascular critical care is warranted.
Abstract:
Intravenous positive inotropic agents play an important role in treating acute decompensation of patients with heart failure due to left ventricular systolic dysfunction. Levosimendan is a new positive inotropic agent having ATP-dependent potassium-channel opening, and calcium-sensitizing effects, which increases cardiac contractility and performance along with vasodilatatory action without increasing myocardial oxygen demand. We report a case of a 12-year-old girl with viral myocarditis, dilated cardiomyopathy, biventricular failure with severe left ventricular dysfunction, refractory to standard management, and who was successfully improved with levosimendan.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care